Arvinas: Pay

Arvinas paid its 5 named executives $17.7M in total in FY2025 (Dec).

Pay of each named executive

John Houston, Ph.D.Former President and Chief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Noah Berkowitz, M.D., Ph.D.Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
2 years
Andrew SaikChief Financial Officer and Treasurer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
2 years
Angela Cacace, Ph.D.Chief Scientific Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Ian Taylor, Ph.D.Former President of Research and Development
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $5.1M. The CEO of Arvinas was paid $6.5M, 29% above the median.

  1. 1Cogent Biosciences
  2. 2Arcus Biosciences
  3. 3Arvinas
  4. 4Intellia Therapeutics
  5. 5Relay Therapeutics
  6. 6Regenxbio
  7. 7Alector, Inc.Not disclosed
  8. 8Arrowhead PharmaceuticalsNot disclosed
  9. 9BiohavenNot disclosed
  10. 10Crinetics Pharmaceuticals, Inc.Not disclosed
  11. 11Denali Pharmaceuticals, Inc.Not disclosed
  12. 12ErascaNot disclosed
  13. 13KalVista Pharmaceuticals, Inc. ()Not disclosed
  14. 14Prothena Corporation plc ()Not disclosed
  15. 15SpringWorks Therapeutics, Inc.Not disclosed
  16. 16Syndax PharmaceuticalsNot disclosed
  17. 17XencorNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.